About us
Your trusted end-to-end CDMO partner
Find out moreWho we are
We are OneSource. The multimodal specialty pharma CDMO with end-to-end capabilities across tech platforms and therapeutic modalities.
With three decades of experience in specialized drug development and manufacturing, we are able to consistently deliver comprehensive solutions efficiently and effectively across various technology platforms and therapeutic modalities.
Our team of over 1,200 professionals, including more than 200 techno-commercial experts has one goal – to work closely with our partners and make their vision come to life.
We’re here to change the way you think about CDMOs. We deliver your ambitions with agility and flexibility. Why? Because your success is our success.
What we do
Drug-device combinations
We have over 30 years of experience in developing drug-device combinations. Our multi-disciplinary team can solve any design, compatibility, device interaction and stability challenges that arise during the development and manufacturing process. We specialize in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors.
Complex injectables
With over 25 years of domain experience in sterile injectables, we can leverage our deep expertise in formulation and analytical development, all the way to optimization, scale-up and transfer of lyophilization cycles.
Biologics
Our integrated services offer comprehensive biologics solutions – all under one roof. We can support the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and RNA products.
Soft gelatin capsules
We are masters in a spectrum of soft gelatin capsule technologies. This means that we can cater to a variety of capsule shapes and sizes, as well as innovative formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps and suppositories.
Explore our capabilities
CapabilitiesOur journey
OneSource has a strong proven track record of manufacturing excellence in the pharmaceutical and biotechnology industries.
Our values
Integrity
We adhere to ethical practices and maintain transparency in our conduct, fostering a culture of trust and integrity in the organisation.
Competency
We develop and effectively apply our knowledge, abilities and skills to successfully and consistently deliver desired outcomes.
Efficiency
We are agile and collaborative to deliver quicker and better results.
Not just another pharmaceutical CDMO
Contact our team
End-to-end services across multiple modalities
From early stage development to commercialization and lifecycle management, we can advise and deliver on all your unique requirements, taking care of the complexities so you don’t have to.
Customer-first Always
We are reliable, transparent and fast. With our collaborative and adaptable approach, you can count on us to ensure your project’s success at every stage.
Unique breadth of technical expertise
Our industry-leading expertise supports you from concept to market, including formulation and development, commercialization and life cycle management. Our team provides specialized assistance in drug device development, regulatory support and procurement.
Robust quality and compliance standards
From our regulatory approved facilities to robust Quality Management Systems (QMS) and track record of 138 successful audits across our sites, we ensure quality, compliance and confidentiality at every stage, so you can launch with confidence.
State-of-the-art facilities: A blueprint for success
When it comes to our facilities, there is no room for compromise. That’s why our cutting-edge development and manufacturing sites are equipped with the latest technology and highest standards. Approved by various regulatory bodies, including the FDA, MHRA, ANVISA, TGA, WHO and MCC, our facilities speak for our commitment to excellence.
We currently operate five state-of-the-art facilities in Bengaluru, India, with plans for future expansion coming soon.
Leadership team
Advisory team
Dr. Claudio Albrecht
Dr. Albrecht, with a Ph.D. in Law, has 30+ years in pharma. He started at Sandoz in 1987, led Ratiopharm Group’s growth as CEO, co-founded CoMeth, and oversaw Actavis Group’s $6 billion sale to Watson. He also co-founded Albrecht, Prock & Partners AG and was CEO of STADA AG until 2018.
Carl-Åke Carlsson
Mr. Carlsson, with over 30 years in the pharmaceutical industry, has a strong Scandinavian background. Born in Norway with Swedish roots and having worked in Denmark, he led Xellia Pharmaceuticals as CEO for 15 years, growing the company to $300 million in annual sales and managing 1,800 employees.
Dr. Rashmi H Barbhaiya
Dr. Barbhaiya, is a pharmaceutical executive with global experience. He spent 21 years at Bristol-Myers Squibb, then became President of R&D at Ranbaxy, where he developed a novel anti-malarial drug. In 2005, he co-founded Advinus Therapeutics, integrating drug discovery with pre-clinical development to boost R&D productivity.
Dr. Aleksandar Danilovski (Sasa)
Dr. Danilovski, with nearly 30 years in pharma, is the founder of DALISCO d.o.o. and advises companies in Europe and the U.S. He has been Chief Scientific Officer at Xellia Pharmaceuticals, VP of European R&D at Barr Laboratories, and on the Management Board at PLIVA Pharmaceuticals.
Dr. Aqeel A. Fatmi
Dr. Fatmi, with over 40 years in pharma, retired in 2016 as Chief Science Officer at Patheon. He co-founded the Georgia Combinatorial Chemistry Center and held senior roles at Solvay Pharmaceuticals. He also serves on the University of Georgia’s School of Pharmacy advisory board.